{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:27:37Z","timestamp":1789244857151,"version":"build-2803163510"},"reference-count":55,"publisher":"PeerJ","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n               <jats:title>Objective<\/jats:title>\n               <jats:p>This study aims to investigate the clinicopathological features, treatment modalities, and prognostic factors associated with salivary duct carcinoma (SDC).<\/jats:p>\n            <\/jats:sec>\n            <jats:sec>\n               <jats:title>Methods<\/jats:title>\n               <jats:p>A retrospective analysis was conducted on the clinicopathological data of 61 patients with SDC admitted to Shanxi Cancer Hospital from January 2010 to February 2024. This study focused on their demographic information, treatment regimens, clinical outcomes, and overall prognosis.<\/jats:p>\n            <\/jats:sec>\n            <jats:sec>\n               <jats:title>Results<\/jats:title>\n               <jats:p>A total of 61 patients with SDC were included in this study, of whom 45 (73.77%) had primary tumors in the parotid gland, 44 (72.13%) were in stage IV at the initial visit, 35 (57.38%) had cervical lymph node metastases, and two (3.28%) had distant metastasis at the first visit. Immunohistochemical (IHC) staining showed that 54 cases (88.52%) were positive for androgen receptor (AR), and 25 cases (40.98%) were positive for human epidermal growth factor receptor 2 (HER-2). Two patients did not undergo surgical treatment due to distant metastasis and received palliative chemoradiotherapy. Fifty-nine patients underwent radical surgery, and of these, 52 (88.14%) received postoperative adjuvant treatment, including chemoradiotherapy or radiotherapy alone. The median overall survival (OS) time was 20 months for the non-surgery group (<jats:italic>n<\/jats:italic>\u00a0=\u00a02), 79 months (95% CI [72.60\u201385.40]) for the surgery and chemoradiotherapy group (<jats:italic>n<\/jats:italic>\u00a0=\u00a022), 61 months (95% CI [49.11\u201372.90]) for the surgery and radiotherapy group (<jats:italic>n<\/jats:italic>\u00a0=\u00a030), 20 months (95% CI [13.60\u201326.40]) for the surgery-only group (<jats:italic>n<\/jats:italic>\u00a0=\u00a07). The median OS was significantly higher in the adjuvant treatment groups (radiotherapy or chemoradiotherapy) compared with the surgery only or non-surgery groups (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.05).<\/jats:p>\n            <\/jats:sec>\n            <jats:sec>\n               <jats:title>Conclusion<\/jats:title>\n               <jats:p>SDC is a rare and highly aggressive malignancy with a poor prognosis. Surgical margins, American Joint Committee on Cancer (AJCC) stage, and treatment method were identified as adverse prognostic factors affecting the OS of patients with SDC. Radical surgery remains the primary treatment for salivary duct carcinoma while adjuvant therapy significantly reduces recurrence rates and improves survival. However, the overall prognosis remains challenging, highlighting the need for novel therapeutic strategies.<\/jats:p>\n            <\/jats:sec>","DOI":"10.7717\/peerj.19626","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T08:34:38Z","timestamp":1751618078000},"page":"e19626","source":"Crossref","is-referenced-by-count":5,"title":["Clinical diagnosis, treatment, and survival analysis of 61 cases of salivary duct carcinoma: a retrospective study"],"prefix":"10.7717","volume":"13","author":[{"given":"Shubin","family":"Dong","sequence":"first","affiliation":[{"name":"Department of Head and Neck Surgery, Shanxi Provincial Cancer Hospital, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengru","family":"Li","sequence":"additional","affiliation":[{"name":"Academy of Medical Sciences, Shanxi Medical University, Taiyuan, Shanxi Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Zhang","sequence":"additional","affiliation":[{"name":"First Clinical Medical School, Shanxi Medical University, Taiyuan, Shanxi Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowei","family":"Feng","sequence":"additional","affiliation":[{"name":"School of Stomatology, Shanxi Medical University, Taiyuan, Shanxi Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Shanxi Provincial Cancer Hospital, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Chang","sequence":"additional","affiliation":[{"name":"Shanxi Provincial Cancer Hospital, Department of Pathology, Taiyuan, Shanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Shanxi Provincial Cancer Hospital, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4443","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"key":"10.7717\/peerj.19626\/ref-1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/apm.13090","article-title":"Salivary gland tumours in Iceland 1986\u20132015: a nationwide epidemiological analysis over a 30-year time period","volume":"129","author":"Aegisdottir","year":"2021","journal-title":"Apmis"},{"key":"10.7717\/peerj.19626\/ref-2","doi-asserted-by":"publisher","first-page":"224","DOI":"10.6004\/jnccn.2022.0016","article-title":"NCCN guidelines\u00ae insights: head and neck cancers, version 1.2022","volume":"20","author":"Caudell","year":"2022","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"10.7717\/peerj.19626\/ref-3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s13193-018-0853-4","article-title":"Salivary duct carcinoma of parotid gland: a rare tumor","volume":"10","author":"Chidananda-Murthy","year":"2019","journal-title":"Indian Journal of Surgical Oncology"},{"key":"10.7717\/peerj.19626\/ref-4","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.3332\/ecancer.2020.1055","article-title":"A 10-year review of primary major salivary gland cancers","volume":"14","author":"Cruz","year":"2020","journal-title":"Ecancermedicalscience"},{"key":"10.7717\/peerj.19626\/ref-5","doi-asserted-by":"publisher","first-page":"4623","DOI":"10.1158\/1078-0432.Ccr-16-0637","article-title":"Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer","volume":"22","author":"Dalin","year":"2016","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"10.7717\/peerj.19626\/ref-6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/cancers9020017","article-title":"Androgen receptor signaling in salivary gland cancer","volume":"9","author":"Dalin","year":"2017","journal-title":"Cancers"},{"issue":"12","key":"10.7717\/peerj.19626\/ref-7","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1097\/pas.0000000000002307","article-title":"Expanding the molecular spectrum of carcinoma ex pleomorphic adenoma: an analysis of 84 cases with a novel HMGA2::LINC02389 fusion","volume":"48","author":"De\u00a0Lima-Souza","year":"2024","journal-title":"American Journal of Surgical Pathology"},{"key":"10.7717\/peerj.19626\/ref-8","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/moo.0000000000000436","article-title":"Salivary duct carcinoma","volume":"26","author":"D\u2019Heygere","year":"2018","journal-title":"Current Opinion in Otolaryngology & Head and Neck Surgery"},{"key":"10.7717\/peerj.19626\/ref-9","doi-asserted-by":"publisher","first-page":"669486","DOI":"10.3389\/fonc.2021.669486","article-title":"Corrigendum: salivary gland carcinoma: novel targets to overcome treatment resistance in advanced disease","volume":"11","author":"Di\u00a0Villeneuve","year":"2021","journal-title":"Frontiers in Oncology"},{"key":"10.7717\/peerj.19626\/ref-10","doi-asserted-by":"publisher","first-page":"693394","DOI":"10.3389\/fonc.2021.693394","article-title":"HER2 positivity in histological subtypes of salivary gland carcinoma: a systematic review and meta-analysis","volume":"11","author":"Egebjerg","year":"2021","journal-title":"Frontiers in Oncology"},{"key":"10.7717\/peerj.19626\/ref-11","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.wneu.2020.05.180","article-title":"A case of salivary duct carcinoma intracranial invasion due to perineural invasion through the facial nerve","volume":"140","author":"Enomoto","year":"2020","journal-title":"World Neurosurgery"},{"key":"10.7717\/peerj.19626\/ref-12","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1200\/jco.21.00449","article-title":"Management of salivary gland malignancy: ASCO guideline","volume":"39","author":"Geiger","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.7717\/peerj.19626\/ref-13","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/dc.24426","article-title":"Oncocytic features in salivary duct carcinoma, a potential pitfall for misdiagnosis as Warthin tumor in fine needle aspiration specimens: a cytomorphologic analysis of 14 cases","volume":"48","author":"Goswami","year":"2020","journal-title":"Diagnostic Cytopathology"},{"key":"10.7717\/peerj.19626\/ref-14","doi-asserted-by":"publisher","first-page":"e1234","DOI":"10.1002\/lio2.1234","article-title":"A 22-year single institution review of 119 cases of salivary duct carcinoma","volume":"9","author":"Han","year":"2024","journal-title":"Laryngoscope Investigative Otolaryngology"},{"key":"10.7717\/peerj.19626\/ref-15","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1634\/theoncologist.2019-0841","article-title":"The benefits of adjuvant trastuzumab for HER-2-positive salivary gland cancers","volume":"25","author":"Hanna","year":"2020","journal-title":"Oncologist"},{"key":"10.7717\/peerj.19626\/ref-16","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1200\/jop.19.00626","article-title":"Long-term durable response after treatment of metastatic salivary duct carcinoma with pembrolizumab","volume":"16","author":"Harwood","year":"2020","journal-title":"JCO Oncology Practice"},{"key":"10.7717\/peerj.19626\/ref-17","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00428-023-03598-3","article-title":"Prognostic value and clinicopathological roles of the tumor immune microenvironment in salivary duct carcinoma","volume":"483","author":"Hirai","year":"2023","journal-title":"Virchows Archiv"},{"key":"10.7717\/peerj.19626\/ref-18","doi-asserted-by":"publisher","first-page":"4069","DOI":"10.1200\/jco.21.01983","article-title":"Androgen receptor pathway in salivary gland cancer","volume":"39","author":"Ho","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.7717\/peerj.19626\/ref-19","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/jjco\/hyac008","article-title":"Systemic therapy for salivary gland malignancy: current status and future perspectives","volume":"52","author":"Imamura","year":"2022","journal-title":"Japanese Journal of Clinical Oncology"},{"key":"10.7717\/peerj.19626\/ref-20","doi-asserted-by":"publisher","first-page":"489","DOI":"10.4132\/jptm.2020.07.19","article-title":"Primary squamous cell carcinoma of the salivary gland: immunohistochemical analysis and comparison with metastatic squamous cell carcinoma","volume":"54","author":"Jo","year":"2020","journal-title":"Journal of Pathology and Translational Medicine"},{"key":"10.7717\/peerj.19626\/ref-21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1200\/jco.20.01894","article-title":"Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: updated results of ALTERNATIVE","volume":"39","author":"Johnston","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.7717\/peerj.19626\/ref-22","doi-asserted-by":"publisher","first-page":"886","DOI":"10.3892\/mco.2017.1226","article-title":"Salivary duct carcinoma treated with cetuximab-based targeted therapy: a case report","volume":"6","author":"Kawahara","year":"2017","journal-title":"Molecular and Clinical Oncology"},{"key":"10.7717\/peerj.19626\/ref-23","doi-asserted-by":"publisher","first-page":"17588359221119538","DOI":"10.1177\/17588359221119538","article-title":"Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma","volume":"14","author":"Kawakita","year":"2022","journal-title":"Therapeutic Advances in Medical Oncology"},{"key":"10.7717\/peerj.19626\/ref-24","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1177\/0284185118776504","article-title":"Detection of loco-regional recurrence in malignant head and neck tumors: a comparison of CT, MRI, and FDG PET-CT","volume":"60","author":"Kim","year":"2019","journal-title":"Acta Radiologica"},{"key":"10.7717\/peerj.19626\/ref-25","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/BF00301495","article-title":"Salivary duct carcinoma. A group of salivary gland tumors analogous to mammary duct carcinoma","volume":"192","author":"Kleinsasser","year":"1968","journal-title":"Arch Klin Exp Ohren Nasen Kehlkopfheilkd"},{"key":"10.7717\/peerj.19626\/ref-26","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1002\/hed.27034","article-title":"The implicated clinical factors for outcomes in 304 patients with salivary duct carcinoma: multi-institutional retrospective analysis in Japan","volume":"44","author":"Kusafuka","year":"2022","journal-title":"Head and Neck"},{"key":"10.7717\/peerj.19626\/ref-27","doi-asserted-by":"publisher","first-page":"101204","DOI":"10.1016\/j.adro.2023.101204","article-title":"Clinicopathologic factors and their association with outcomes of salivary duct carcinoma: a multicenter experience","volume":"8","author":"Laughlin","year":"2023","journal-title":"Advances in Radiation Oncology"},{"key":"10.7717\/peerj.19626\/ref-28","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.annpat.2024.02.005","article-title":"Salivary gland tumors: 2022 WHO blue book and beyond","volume":"44","author":"L\u00e9pine","year":"2024","journal-title":"Annales de Pathologie"},{"key":"10.7717\/peerj.19626\/ref-29","doi-asserted-by":"publisher","first-page":"105905","DOI":"10.1016\/j.oraloncology.2022.105905","article-title":"Anti-PD-1 plus anti-HER2 and chemotherapy showed superior and durable clinical benefit in a patient with advanced salivary duct carcinoma","volume":"130","author":"Ma","year":"2022","journal-title":"Oral Oncology"},{"key":"10.7717\/peerj.19626\/ref-30","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.1007\/s00405-024-08627-8","article-title":"The extent of androgen receptor and HER2 expression allows for targeted therapy in most cases of salivary duct carcinoma: analysis of clinical and histopathological data in a tertiary care center","volume":"281","author":"Mayer","year":"2024","journal-title":"European Archives of Oto-Rhino-Laryngology"},{"key":"10.7717\/peerj.19626\/ref-31","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1002\/cncr.32792","article-title":"Distant metastasis of salivary gland cancer: incidence, management, and outcomes","volume":"126","author":"Mimica","year":"2020","journal-title":"Cancer"},{"key":"10.7717\/peerj.19626\/ref-32","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1038\/s41379-020-0576-2","article-title":"Molecular patterns in salivary duct carcinoma identify prognostic subgroups","volume":"33","author":"Mueller","year":"2020","journal-title":"Modern Pathology"},{"issue":"3","key":"10.7717\/peerj.19626\/ref-33","doi-asserted-by":"publisher","first-page":"720","DOI":"10.3390\/jcm11030720","article-title":"Targeted therapy, chemotherapy, immunotherapy and novel treatment options for different subtypes of salivary gland cancer","volume":"11","author":"Mueller","year":"2022","journal-title":"Journal of Clinical Medicine"},{"key":"10.7717\/peerj.19626\/ref-34","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.1007\/s00432-022-04278-6","article-title":"Incidence and clinical outcome of primary carcinomas of the major salivary glands: 10-year data from a population-based state cancer registry in Germany","volume":"149","author":"Nachtsheim","year":"2023","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"10.7717\/peerj.19626\/ref-35","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/cncy.22288","article-title":"Salivary duct carcinoma: updates in histology, cytology, molecular biology, and treatment","volume":"128","author":"Nakaguro","year":"2020","journal-title":"Cancer Cytopathology"},{"key":"10.7717\/peerj.19626\/ref-36","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.path.2020.09.010","article-title":"Salivary duct carcinoma: an aggressive salivary gland carcinoma with morphologic variants, newly identified molecular characteristics, and emerging treatment modalities","volume":"14","author":"Rahman","year":"2021","journal-title":"Surgical Pathology Clinics"},{"key":"10.7717\/peerj.19626\/ref-37","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1097\/pas.0000000000001636","article-title":"The decline of salivary adenocarcinoma not otherwise specified as a tumor entity: reclassification using contemporary immunohistochemical profiling and diagnostic criteria","volume":"45","author":"Rooper","year":"2021","journal-title":"American Journal of Surgical Pathology"},{"key":"10.7717\/peerj.19626\/ref-38","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.humpath.2019.08.009","article-title":"Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: clinicopathological and prognostic implications","volume":"93","author":"Santana","year":"2019","journal-title":"Human Pathology"},{"key":"10.7717\/peerj.19626\/ref-39","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000534516","article-title":"Efficacy of cetuximab combined with paclitaxel in patients with recurrent salivary gland carcinoma: a retrospective observational study","volume":"86","author":"Sato","year":"2024","journal-title":"ORL; Journal of Oto-Rhino-Laryngology and Its Related Specialties"},{"key":"10.7717\/peerj.19626\/ref-40","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1007\/s00066-019-01499-6","article-title":"Outcome and management of rare high-grade salivary adenocarcinoma: the important role of adjuvant (chemo)radiotherapy","volume":"195","author":"Scherl","year":"2019","journal-title":"Strahlentherapie und Onkologie"},{"key":"10.7717\/peerj.19626\/ref-41","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.oraloncology.2017.09.008","article-title":"Salivary duct carcinoma: an aggressive salivary gland malignancy with opportunities for targeted therapy","volume":"74","author":"Schmitt","year":"2017","journal-title":"Oral Oncology"},{"key":"10.7717\/peerj.19626\/ref-42","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/cncr.33968","article-title":"Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified","volume":"128","author":"Sousa","year":"2022","journal-title":"Cancer"},{"key":"10.7717\/peerj.19626\/ref-43","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1007\/s00405-019-05454-0","article-title":"Parotid salivary duct carcinoma: a single institution\u2019s 20-year experience","volume":"276","author":"Stodulski","year":"2019","journal-title":"European Archives of Oto-Rhino-Laryngology"},{"key":"10.7717\/peerj.19626\/ref-44","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1200\/jco.18.00545","article-title":"Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma","volume":"37","author":"Takahashi","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.7717\/peerj.19626\/ref-45","doi-asserted-by":"publisher","first-page":"59023","DOI":"10.18632\/oncotarget.19812","article-title":"Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification","volume":"8","author":"Takase","year":"2017","journal-title":"Oncotarget"},{"key":"10.7717\/peerj.19626\/ref-46","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.hoc.2021.05.011","article-title":"Salivary gland cancers","volume":"35","author":"Tchekmedyian","year":"2021","journal-title":"Hematology\/Oncology Clinics of North America"},{"key":"10.7717\/peerj.19626\/ref-47","doi-asserted-by":"publisher","first-page":"102069","DOI":"10.1016\/j.ctrv.2020.102069","article-title":"Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: a systematic review","volume":"89","author":"Uijen","year":"2020","journal-title":"Cancer Treatment Reviews"},{"key":"10.7717\/peerj.19626\/ref-48","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ejca.2018.12.035","article-title":"Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma","volume":"110","author":"Van\u00a0Boxtel","year":"2019","journal-title":"European Journal of Cancer"},{"key":"10.7717\/peerj.19626\/ref-49","doi-asserted-by":"publisher","first-page":"100602","DOI":"10.1016\/j.esmoop.2022.100602","article-title":"Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) clinical practice guideline for diagnosis, treatment and follow-up","volume":"7","author":"Van Herpen","year":"2022","journal-title":"ESMO Open"},{"key":"10.7717\/peerj.19626\/ref-50","doi-asserted-by":"publisher","first-page":"815","DOI":"10.6004\/jnccn.2022.0035","article-title":"Soft tissue sarcoma, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Von Mehren","year":"2022","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"10.7717\/peerj.19626\/ref-51","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00234-012-1014-z","article-title":"Salivary duct carcinomas: clinical and CT and MR imaging features in 20 patients","volume":"54","author":"Weon","year":"2012","journal-title":"Neuroradiology"},{"key":"10.7717\/peerj.19626\/ref-52","volume-title":"WHO classification of head and neck tumours","author":"WHO","year":"2022"},{"key":"10.7717\/peerj.19626\/ref-53","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/lary.30214","article-title":"Role of HER2 in prognosis of salivary duct carcinoma: a systematic review and meta-analysis","volume":"133","author":"Williams","year":"2023","journal-title":"Laryngoscope"},{"key":"10.7717\/peerj.19626\/ref-54","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/0194599815607449","article-title":"Predictors of nodal metastasis in parotid malignancies: a national cancer data base study of 22,653 patients","volume":"154","author":"Xiao","year":"2016","journal-title":"Otolaryngology\u2014Head and Neck Surgery"},{"key":"10.7717\/peerj.19626\/ref-55","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1002\/hed.27382","article-title":"Lymph node ratio-based prognostic model for risk stratification and individualized adjuvant therapy for postoperative major salivary duct carcinoma","volume":"45","author":"Zhang","year":"2023","journal-title":"Head and Neck"}],"container-title":["PeerJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/peerj.com\/articles\/19626.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/19626.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/19626.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/19626.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T08:34:42Z","timestamp":1751618082000},"score":1,"resource":{"primary":{"URL":"https:\/\/peerj.com\/articles\/19626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":55,"alternative-id":["10.7717\/peerj.19626"],"URL":"https:\/\/doi.org\/10.7717\/peerj.19626","archive":["CLOCKSS","LOCKSS","Portico"],"relation":{},"ISSN":["2167-8359"],"issn-type":[{"value":"2167-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]},"article-number":"e19626"}}